ENTASIS THERAPEUTICS HLDGS I's ticker is ETTX and the CUSIP is 293614103. A total of 23 filers reported holding ENTASIS THERAPEUTICS HLDGS I in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,106,000 | +22.2% | 502,622 | +3.9% | 0.00% | – |
| Q1 2022 | $905,000 | -8.2% | 483,723 | +7.5% | 0.00% | – |
| Q4 2021 | $986,000 | -30.8% | 449,955 | +5.6% | 0.00% | – |
| Q3 2021 | $1,424,000 | +27.0% | 426,235 | +1.5% | 0.00% | – |
| Q2 2021 | $1,121,000 | +155.4% | 419,997 | +104.7% | 0.00% | – |
| Q1 2021 | $439,000 | +33.4% | 205,166 | +54.1% | 0.00% | – |
| Q4 2020 | $329,000 | +63.7% | 133,159 | +34.8% | 0.00% | – |
| Q3 2020 | $201,000 | +24.8% | 98,759 | +81.1% | 0.00% | – |
| Q2 2020 | $161,000 | +11.8% | 54,526 | 0.0% | 0.00% | – |
| Q1 2020 | $144,000 | -46.9% | 54,526 | 0.0% | 0.00% | – |
| Q4 2019 | $271,000 | -14.8% | 54,526 | 0.0% | 0.00% | – |
| Q3 2019 | $318,000 | +0.3% | 54,526 | +11.1% | 0.00% | – |
| Q2 2019 | $317,000 | -4.5% | 49,097 | 0.0% | 0.00% | – |
| Q1 2019 | $332,000 | +66.0% | 49,097 | 0.0% | 0.00% | – |
| Q4 2018 | $200,000 | – | 49,097 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,176,378 | $2,517,000 | 0.81% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,020,748 | $2,184,000 | 0.02% |
| Eventide Asset Management | 590,602 | $1,264,000 | 0.02% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 29,031 | $62,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 120,000 | $257,000 | 0.01% |
| Jaffetilchin Investment Partners, LLC | 11,000 | $24,000 | 0.00% |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 41,877 | $90,000 | 0.00% |
| Renaissance Technologies | 786,606 | $1,683,000 | 0.00% |
| Squarepoint Ops LLC | 91,725 | $196,000 | 0.00% |
| Janney Montgomery Scott LLC | 70,930 | $152,000 | 0.00% |